

9 September 2015

ASX Limited
Level 6, Exchange Centre
20 Bridge Street
Sydney NSW 2000

COMPANY ANNOUNCEMENTS

Cellmid Limited – CDY Results of the Extraordinary General Meeting of Members

We advise that:

a) In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, all the following resolutions were passed without a poll at the Extraordinary General Meeting of Cellmid Limited (**Company**) on Wednesday 9 September 2015:

Ordinary Business:

RESOLUTION 1 – ELECTION OF A DIRECTOR – MR BRUCE GORDON

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

"That Mr Bruce Gordon, who has been appointed by the Directors of Cellmid Limited since the last Annual General Meeting, retires as a Director, and being eligible, offers himself for election, hereby be elected as a Director."

RESOLUTION 2 – ELECTION OF DIRECTOR – DR EDWARD FINTAN WALTON

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

That Dr Edward Fintan Walton, who has been appointed by the Directors of Cellmid Limited since the last Annual General Meeting, retires as a Director, and being eligible, offers himself for election, hereby be elected as a Director."

Special Business

RESOLUTION 3 – RATIFICATION OF PRIOR ISSUE OF ORDINARY SHARES UNDER PLACEMENT

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

"That for the purposes of ASX Listing Rule 7.4 and all other purposes, approval is given to the issue and allotment of 110,000,000 fully paid ordinary shares at \$0.03, as detailed in the Explanatory Statement."

RESOLUTION 4 – APPROVAL FOR THE ISSUE OF ORDINARY SHARES UNDER PLACEMENT

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

“That, for the purposes of ASX Listing Rule 7.1, and for all other purposes, approval is given for the issue and allotment of 23,333,333 fully paid ordinary shares at \$0.03 per share as detailed in the Explanatory Statement.”

b) A summary of valid and eligible proxies received for the above meeting was as follows:

	For	Open	Against	Abstain	Excluded
Resolution 1 Election of a Director – Mr Bruce Gordon	263,227,265 86.83%	38,840,788 12.81%	1,076,988 0.36%	125,000	NIL
Resolution 2 Election of a Director – Dr Edward Fintan Walton	263,367,265 86.87%	38,840,788 12.81%	976,988 0.32%	85,000	NIL
Resolution 3 Ratification of prior issue of ordinary shares under placement	220,088,910 84.01%	38,860,788 14.84%	3,003,309 1.15%	146,668	41,170,366
Resolution 4 Approval for the issue of ordinary shares under placement	245,232,369 84.30%	38,860,788 13.36%	6,796,882 2.34%	12,380,002	NIL

End

Contact:

María Halasz

Managing Director and CEO

T +612 9221 6830

Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company with two revenue generating businesses; a consumer health and a midkine division. The Company’s consumer health division owns proprietary technologies and products around FGF5 inhibition, a novel mechanism for increasing hair growth and reducing hair loss. The midkine division is focused on developing drug candidates in oncology and nephropathy, while out-licensing diagnostics for a number of cancer indications. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the novel target midkine and midkine antagonists globally. For further information please see www.cellmid.com.au and www.evolisproducts.com.au.